Valuation: Veradermics, Incorporated

Market Cap 4.42B 3.86B 3.57B 3.28B 6.21B 426B 6.32B 42.62B 16.74B 208B 16.6B 16.24B 718B P/E 2026 *
-35.9x
P/E 2027 * -38.8x
Enterprise Value 4.42B 3.86B 3.57B 3.28B 6.21B 426B 6.32B 42.62B 16.74B 208B 16.6B 16.24B 718B EV / Sales 2026 *
-
EV / Sales 2027 * 511x
Free-Float
97.26%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Veradermics, Incorporated

1 day-14.45%
1 week-15.27%
Current month-13.92%
1 month+16.36%
3 months+42.78%
1 week 104.46
Extreme 104.46
129.8
1 month 86.83
Extreme 86.83
131.24
Current year 32
Extreme 32
131.24
1 year 32
Extreme 32
131.24
3 years 32
Extreme 32
131.24
5 years 32
Extreme 32
131.24
10 years 32
Extreme 32
131.24
Manager TitleAgeSince
Chief Executive Officer 31 2022-11-30
President 36 2020-07-31
Director of Finance/CFO 40 2023-09-30
Director TitleAgeSince
Director/Board Member 31 2019-09-30
Director/Board Member 84 2021-08-31
Director/Board Member 75 2021-08-31
Date Insider Type Main position Quantity % Market Cap.
5/1/26
Suvretta Capital Management LLC
FreeCompany 300,000 0.8034%
2/5/26
Longitude Capital Management Co LLC
ConversionCompany 8,232,746 -
2/4/26
Suvretta Capital Management LLC
BuyCompany 282,674 -
Change 5-day change 1-year change 3-year change Capi.($)
-14.45%-15.27% - - 5.17B
+1.08%-3.93%+48.03%+160.13% 1,031B
+1.19%-3.52%+51.70%+56.36% 595B
+4.21%+1.79%+33.48%+87.04% 431B
+0.42%-1.16%+29.43%+22.27% 326B
+1.03%-0.84%+29.58%+45.08% 277B
+0.49%-5.44%+21.00%+22.32% 263B
+3.70%+2.19%+24.27%+63.38% 193B
+3.49%+1.08%+24.08%+76.58% 164B
+1.29%+3.67%+2.15%-30.78% 141B
Average -0.02%-2.39%+29.30%+55.82% 342.7B
Weighted average by Cap. +1.63%-2.07%+37.11%+82.48%

Financials

2026 *2027 *
Net sales - 8.66M 7.57M 7M 6.42M 12.15M 834M 12.37M 83.46M 32.79M 407M 32.51M 31.8M 1.41B
Net income -109M -95.45M -88.27M -81M -153M -10.52B -156M -1.05B -414M -5.14B -410M -401M -17.74B -122M -106M -98.31M -90.22M -171M -11.72B -174M -1.17B -461M -5.72B -457M -447M -19.76B
Net Debt - -
Logo Veradermics, Incorporated
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
Employees
24
Date Price Change Volume
26-07-16 US$105.83 -14.45% 1,454,766
26-07-15 US$123.70 +12.28% 1,338,019
26-07-14 US$110.17 -0.01% 524,998
26-07-13 US$110.18 -7.88% 454,337
26-07-10 US$119.60 -4.25% 351,351
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
105.83USD
Average target price
161.00USD
Spread / Average Target
+52.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MANE Stock